Rapid allergen vaccination (RA V) is the updated term for what was previously called rush immunotherapy and rapid desensitization. RAV offers several advantages over traditional immunotherapy-that is, conventional allergen vaccination (CAV)-in terms offaster efficacy, better compliance, and cost-effectiveness. We used a 3-hour RAV protocol to treat 137 allergy patients. All patients were premedicated with either prednisone or prednisolone and an HI antihistamine. Following the RA V procedure, all patients resumed a CAV schedule. Only six patients (4.4 %) experienced a mild systemic reaction to RA V, and five (3.6 %) experienced a mild systemic reaction to CAV 14 to 77 days later. All six patients who reacted to RAV quickly responded to treatment-in most cases, subcutaneous epinephrine and/or nebuli zed albuterol-and were sent home after a short period of observation. Compliance rates at 3, 6, and 12 months were 96.4, 94.2, and 75.9 %, respectively, which is an improvement over rates previously reported for patients undergoing CAV therapy. We conclude that the 3-hour RA V proto col can be safely and successfully administered. Patients who undergo RAV are more compliant with their subsequent CAV regimen than are patients who do not undergo RAV because signs of clinical efficacy manifest almost immediately and because RAV is associated with substantially lower rates of systemic reactions. Moreover, RAV is asso ciated with less morbidity and less expense. Our findin gs should encourage physicians who treat allergy patients to give further consideration to using RAV.
Introduction
Allergen vaccination is effective in the treatment of allergic rhinitis,' :" allergic asthma,"!' and Hymenoptera allergy .I-" Conventional allergen vaccination (CAV) involves weekly inoculations of gradually increasing concentrations until a maintenance dose is reached. Thereafter, vaccinations are administered biweekly or monthly for 3 to 5 years. Ideally, the CAV protocol induces immunity and results in remission of disease. Measurable levels of immunoglobulin G4 following CAV therapy support the fact that it does alter the immune system. The mechanism of action appears to involve a decrease in type 2 T-helper cells and an increase in type I T-helper cells, which leads to a decrease in the expression of allergic disease.
However, inappropriate discontinuation of CA V by patients is common because compliance requires a longterm commitment and discipline. Patients will also discontinue therapy prematurely if they perceive that they are not obtaining any immediate benefit. Reports of compliance rates greater than 60 % are unusual.l' :"
Rapid allergen vaccination (RA V)-previously called rush immunoth erapy and rapid desensiti zation-administered prior to CAV has several advantages over CA V alone. First, RAV should improve compliance, primarily because patients experience clinical efficacy more quickly than they do without it. More rapid efficacy also reduces morbidity. Finally, because RA V does not require up to 6 months of weekly "build-up" injections, both direct and indirect costs to the patient are reduced. By receiving a series of increasingly more concentrated immuni zing doses , patients can achieve an effec tive maintenance dose in a period of ju st I to 7 days.IO·16. 17 The major controversy over RAV concerns its safetyspecifically, the potentially higher risk of syste mic reactions that could resu lt in anaphy lax is or death." :" Rates of systemic reactions to RAV have been reporte d to be greater than 15% in some studie s, 17, [20] [21] [22] [23] [24] and Portnoy et al reported a systemic reaction rate of23 %. 22 Reported rates of systemic reactions to CAV have varied grea tly, from 0.8 to 46.7 %. 23 In this article, we describe our study of the safety of a practical RAV protocol for office -based phys icians who treat patien ts with allergies .
Patients and methods
Patient selection . Our study population was made up of 137 patients-6 1 males and 76 females, aged 2 to 68 years-who were selected from the case load of an officebased allergy practice. All patients had at least one of the following conditions: allergic rhiniti s (137 patients), allergic asthma ( 109), and chronic sinusitis (62); 64 of these patients also had sinusitis-associated headaches. Each was positive for immunoglobulin E (IgE) on percutaneous testing, and eac h had a histo ry consistent with allergymediated disease. Exclusion criteria included a history of anaphylaxis, a forced expiratory volume in I seco nd (FEV I ) of less than 70% of predicted by pulmo nary function testing, a history of card iovascular disease, and current beta blocker use.
Percutaneous allergy testing. For allergy testing, we used I: 10 weight/volume (w/v) glycerinated extracts (Greer Laboratories; Lenoir, N.C.) . The epicutaneous technique was performed with the DermaPik (Greer Laboratories). Intradermal tests were performed with the same allerge n extract in a I:2,000 dilution and administered by 25-gauge syringes . Tests were read 20 minut es after placement. Ski n sensitivity was meas ured in millimeters of wheal and flare. Those whose percutaneous test results were negative underwent further intradermal testing to confirm IgE sensitivity. Individual scratch or intradermal Dilution 1 :1,000,000 1 :1,000,000 1: 100,00 0 1 :100,000 1 :10 ,000 1 :10 ,000 1 :1,000 1 :1,000 tests were considered to be pos itive when either the wheal or flare was at leas t 5 mm larger than the negative diluent control.
A llergen vaccination extract. Vaccine extrac ts were prepared accor ding to stock formu lations used by Greer Laboratories. Both aqueous and glycerinated extrac ts were used to achieve a concentrate of I :100 w/v of the mixed extract. SeriallO-fold dilutions of this concentrate were prepared so that the concentrate was identical to that used for CAV: To minimize systemic reac tions, the targeted final dose durin g the RAV proced ure was a I:1,000 dilution.To reduce proteolytic degradation, separa te vials were used for pollen and mold extrac ts. All extracts were stored at approxim ately 4°C. Serum varied with each individual patient; most patients' serum included a variety of aeroa llergens, including mold, tree, grass, weed, mite, dust, cat, and dog allergens.
Procedurefo r RAV. The option to undergo RAV therapy was offered to all patients in the office practice whom we thought might benefit from immunotherapy. A registered nurse explained the potentially higher risks of RAV, including the risk of anaphylaxis, and written and signed informed consent was obta ined from each of the 137 suitab le candidates who accepted the offer. The procedure was scheduled 1 to 2 weeks later. Prior to RAV, a 3day premedication regimen of a steroid and an antihistamine was prescribed. Patients younger than 5 years received either prednisone or predn isolone at 15 mg twice a day, those aged 5 to 12 years rece ived 20 mg twice aday, and the rest received 30 mg twice a day. The H I antihistamines-cetirizine, fexofenadine, and loratadine-were prescribed at age-appropria te doses.
On the day of the procedure, each patient was reassesse d by history, physical examination, and spirometry. Any docum ented clinical worseni ng (e.g., the presence of upper respiratory tract infection or a decrease in spirome tric values) necessitated that the procedure be rescheduled. Patients receive d injections of a differe nt volume and dilution every 15 minutes for 105 minu tes (table I) . If a patient exper ienced a systemic reaction, the next dose usually was reduced by IO-fold; the patient then resumed the norma l sche dule. We did not alternate arms for injections . Patients who required two simultaneous injections (e.g., separated pollen and fungal allergens) received one in each arm. Patients were obser ved for 30 minutes after their final injection and sent home if they were stable. After the RAV procedure, patients resumed a CAV schedule.
Resu lts
Sys temic reactions to RA V. Systemic reactions Occurred in 6 of the 137 patients (4.4%) betwee n the second and final dose on the day of the RAV proced ure ( (table 3) . All 6 were treated and closely monitored by a trained physician or nurse for at least 60 minutes following the adverse event, and all were sent home within several hours. All but one continued their CAV regimen . All of the systemic reactions occurred within 15 minutes of the offending injection. Treatment usually included one or more of the following: subcutane-ous epinephrine (1 mg/ml ) at a dilution of I:1,000, nebulized albuterol, two sprays in each nostril of azelastine, and diphenhydramine taken orally or intramuscularly. The extract composition in these patients included mold in 6, grass in 5, tree in 4, and weed in 4 (table 3) . Two patients with immediate systemic reactions were exceptional and deserve further discussion. Patient 60, a 29-year-old woman, had an atypical systemic reaction that might not have been allergic in nature . She experienced abdominal pain that caused her severe discomfort. She was treated with subcutaneous epinephrine, nebulized albuterol , and diphenhydramine and sent to the emergency department (ED) for observation . While in the ED, she later received methylprednisolone sodium succinate (125 mg), diphenhydramine (25 mg), ranitidine (50 mg), and ketorolac (30 mg), all intravenously. She said her reaction was similar to urinary bladder "spasms" that she often experienced. Patient 62, a 1O-year-old girl, had a systemic reaction (chest tightness) within 15 minutes of her fourth RAV injection and another reaction the next day; the day-2 reaction was characterized by nasal itching, cough , and headache. She was treated with prednisone (30 mg) for 3 days and recovered.She continued to receive CAV therapy, and she later experie nced another system ic reaction on day 77, which is discussed later in this article .
Systemic reactions to CA V. Five patients (3.6%), including patient 62, experienced a system ic react ion to CAY within 3 months (table 4) . On day 77, patient 62 experienced chest tightness and shortness of breath almost immediately after receiving a weekly allergen vaccination. She was treated in the office and sent home within an hour of the reaction.
All 5 patients who experienced a reaction to CAV completed their vaccination schedule without any further complications. Patient 5, a 48-year-old woman, experienced slight chest tightness approximately 2 hours after she received a weekly allergy injection on day 60. No treatment was necessary.
Patient 8, a 29-year-old man, complained of tightness in the throat, heaviness in the chest , and urticar ia on day 41 after he received his weekly allergen vaccination at work. The nurse at his workplace treated him with 25 mg of diphenhydramine, and he felt better soon thereafter.
Patient 55, a l6-year-old girl, called the office approxi-Vol ume 82, Number 11 mately 2 hours after she had received a weekly allergen vaccination on day 29 and complained of a rash that started on her neck and spread to her stomach . She experienced no respiratory problems. Her rash resolved after treatment with an antihistamine and 30 mg of prednisone, and she continued immunotherapy without any further complications. Patient 116, a 29-year-old woman, received her first weekly injection following RAV without incident. However , 1 week later, she experienced a systemic reaction after receiving her second weekly injection at an urgent care center. According to the records of the urgent care office , she developed urticaria approximately 1 hour after the injection. She returned to the urgent care center and received an intramuscular injection of diphenhydramine. Her systemic reaction comp letely subsided within 10 minutes .
Bu ild-up period. After the RAV procedure, patien ts typically required at least 2 more months of build-up to achieve their targeted maintenance dose.
Comp liance. At 3 months, 132 of the 137 patients (96.4 %) were still following their CAV schedule. At 6 months, 129 patients (94.2%) were still following their regimen, and at 12 months, 104 patients (75.9%) remained compliant.
Discussion
Advantages ofRA V. CAV is often viewed by patients and referring physicians as an inconvenient procedure that can take a year or more to become effective. 14.15 Therefore, a strategy that improves efficacy while maintaining safety would be a welcome addition to the armamentarium. RAV is a promising alternative. Moreover, the enhanced efficacy is cost-effective. In a position paper published in 1998, the World Health Organization stated that "over the past 10 years, costs for asthma and allergic diseases have increased more than for most other diseases.' :" Clearly, it is imperative that we continue to look for ways to decre ase the costs of care for our patients. Patients who choose to unde rgo RAV can avoid the build-up period that stretches up to 6 month s for some patients . With RAV, the cost of therapy can be reduced by as much as 50 % during the first year because 24 weekly vaccinations will not be necessary.
In turn, a less complex and less expen sive treatment can impro ve patient compliance. Studies have shown that inconvenience is the primary reason for high drop-out rates.14.15.26 Our 12-month adherence rate of 75.9% compares favorably with compliance rates for CAV reported by Cohn and Pizzi 14 (50%) and by Lower et al" (56%).
Other possibl e advantages to RAV are less morbid ity, less need for medic ation , and fewer ED visits and hosp italizations.
Complication rates. High rates of systemic reactions assoc iated with RAVin previous studies have discouraged its use. 17.19.21-23 We found that by carefully selecting appropriate patients and by premedicating them, we greatly reduced the risk of systemic reactions.P:" The rates of systemic reactions during RAV (4.4%) and CAY (3.6%) in our study are at the low end of the range reported for CAV (0.8 to 46 .7%) . 23 Nevertheless, most allergists agree that the higher rates report ed in CAV studies far exceed the rates seen in office practice ; those highe r rates are unaccept able in office practice.
Even so, the primary reason for our low rate of complications was that our targeted endpoint dose was low. In previou s studies, high rates of systemic reactions were associated with high doses." By reducing the doses, we lowered the risk of systemic reaction s. Our targeted endpoint dose was one-tenth the dose targeted by Sharkey and Portnoy." In fact, had we reduced the dose 100-fold, our rate of systemic reactions might have been halved becau se patients 21, 60, and 65 all reacted to the most concentrated vial (1: 1,000 dilution).
Observation period. Only one of the six patient s who had a systemic reaction during the RAV protoc ol (patient 62) reported difficulty beyond the 3D-minute observ ation period that we required for all patients. Patient 62 experienced chest tightness within 15 minut es of her fourth injection on day 1 and nasal itching , cough, and headache 1 day later. The lO-year-old girl also experienced chest tightne ss and shortness of breath following an injection on day 77 of therapy. The other five patients who experienced a systemic reaction on day 1 all did so within 15 minute s of the offending injection . The Americ an College of Allergy , Asthma, and Immunology recommends approximately 20 minutes of observation for patient s who undergo CAV and longer for patient s who are at higher risk for complications," which includes RAV patients." We recommend an observation period of 30 minutes.
Age. Age might be an important risk factor for systemic 886 reactions. Of the six patients in our study who experienced reaction s to RA V, four (66.7%) were 13 years of age or younger. However, this age group accounted for only 26.3 % (36/137) of the total number of patients in our study. We are unable to explain the association. We do know that children are less compliant than adults when taking oral medication s.i' -" so perhaps closer scrutiny of their adherence to the premedication regimen would have been wise. 30 -32 We conclude that a 2-to 3-hour RAV protocol with premedication is a safe and effective procedure for selected patients with allergic rhinitis, allergic asthm a, chron ic sinusitis, and associ ated headache. Patients who unde rgo this procedure are able to reach an effe ctive maint enance dose more quickly than do those who undergo CAValone. Of cour se, caution and good clinic al judgment must be exercised when selecting suitable candidat es for therapy .
